RNA (Atrium Therapeutics) Treasury Stock: $0.00 Mil (As of Mar. 2026)


RNA Atrium Therapeutics Inc RNA
12 GF Score
Price $13.44
! 1 Warning Sign
View Full Analysis

What is Atrium Therapeutics Treasury Stock?

Atrium Therapeutics RNA +1.00% 12 Treasury Stock is $0.00 Mil as of Mar. 2026. GuruFocus rates RNA with a GF Score™ of 12/100. The stock has 1 warning sign investors should review.

Treasury stock is the portion of shares that a company keeps in their own treasury. Atrium Therapeutics's treasury stock for the quarter that ended in Mar. 2026 was $0.00 Mil.

Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place.

Atrium Therapeutics Treasury Stock Historical Data

* Premium members only.

The historical data trend for Atrium Therapeutics's Treasury Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Atrium Therapeutics Treasury Stock Chart

Atrium Therapeutics Annual Data
Trend Dec23 Dec24 Dec25
Treasury Stock
0.00 0.00 0.00

Atrium Therapeutics Quarterly Data
Dec23 Dec24 Mar25 Sep25 Dec25 Mar26
Treasury Stock Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00
RNA
12GF Score
Atrium Therapeutics Inc RNA
Treasury Stock is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Atrium Therapeutics Treasury Stock Calculation

The portion of shares that a company keeps in their own treasury. Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place. These shares don't pay dividends, have no voting rights, and should not be included in shares outstanding calculations.

Frequently Asked Questions Learn more about Treasury Stock →
What does a Treasury Stock of $0.00 Mil mean?
Atrium Therapeutics (RNA) has a Treasury Stock of $0.00 Mil as of Mar. 2026. Treasury stock is a contra-equity item that records the amount of stock not issued to shareholders. View historical data for Atrium Therapeutics and its competitors.
Is Atrium Therapeutics' Treasury Stock too high?
Atrium Therapeutics' current Treasury Stock is $0.00 Mil. Overall, Atrium Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Atrium Therapeutics' Treasury Stock compare to CNTN and QTTB?
Atrium Therapeutics' Treasury Stock of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Treasury Stock for a Biotechnology company?
A good Treasury Stock depends on the Biotechnology industry context. However, Treasury Stock should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Treasury Stock mean?
A high Treasury Stock can signal that a stock is expensive relative to its fundamentals. Treasury stock is a contra-equity item that records the amount of stock not issued to shareholders. View historical data for Atrium Therapeutics and its competitors. Atrium Therapeutics's current Treasury Stock is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Atrium Therapeutics stock overvalued right now?
Atrium Therapeutics (RNA) has a current Treasury Stock of $0.00 Mil. The current Treasury Stock is $0.00 Mil. Atrium Therapeutics' overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Treasury Stock calculated?
Treasury Stock is calculated from a company's financial statements. For Atrium Therapeutics (RNA), the current Treasury Stock is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Atrium Therapeutics Business Description

Address 10578 Science Center Drive, Suite 125, San Diego, CA, USA, 92121
Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.
12GF Score

Get the complete analysis for RNA

Treasury Stock is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$13.44
Price